Trials / Completed
CompletedNCT00171145
A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning Time in Patients With Overactive Bladder.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 445 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
This study will assess the efficacy of a 12-week treatment with darifenacin in increasing warning time, the time from first sensation of urgency to voiding, in patients with OAB.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Darifenacin | Darifenacin 15 mg tablets once daily |
| DRUG | Placebo | Placebo tablets once daily |
Timeline
- Start date
- 2004-04-01
- Completion
- 2004-12-01
- First posted
- 2005-09-15
- Last updated
- 2008-01-23
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00171145. Inclusion in this directory is not an endorsement.